Condition: Pancreatic Ductal Adenocarcinoma (PDAC) · Sponsor: University of California, San Diego
This is a Phase 1b trial evaluating the combination of Fostamatinib, a Syk kinase inhibitor currently FDA-approved for chronic idiopathic thrombocytopenia purpura (ITP), with the standard of care chemotherapy agents gemcitabine and nab-paclitaxel, for the perioperative treatment of resectable non metastatic pancreatic ductal adenocarcinoma (PDAC).
This description comes directly from the study's public registry record.
Hitendra Patel, MD · 858-822-5354 · CancerCTO@health.ucsd.edu
Shakeela Dad, PhD · 858-822-5354 · CancerCTO@health.ucsd.edu
Always discuss trial participation with your own doctor first.
| University of California, San Diego Moores Cancer Center | La Jolla, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06639724